FDA Oncologic Drug Committee Agrees That “Kitty Fight” With NCI Should Be Negotiated
In Brief: NCI Tells Cooperative Groups To Submit applications For Extra Multimodality Funds
FDA Delays NDA On BCNU, But New Drug Seminar Still Scheduled
Proposed Guidelines For Clinical Tests Of Oncologic Drugs
UCLA, NYU, Ohio States Must Wait Longer For Comprehensive Status
Contact Planned To Encourage Insurers To Reimburse For Cancer Screening
Rosemond Asks Ban On High Tar, Nicotine Cigarettes
Trending Stories
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”
